← Leaderboards
Deborah Merke
Clinical Center
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseAdultAndrogensAdrenal GlandsCongenital Adrenal Hyperplasia21-Hydroxylase DeficiencyGlucocorticoidsHydrocortisoneDesignDisorder ControlRandomizedGrowthGrowth And Development FunctionChild DevelopmentReportingPhysiologicalHyperandrogenismSafetyConventional TherapyBiochemicalEnrollmentAldosteroneClinical CenterHormonal
Grant awards (23)
Novel treatment approaches: prepubertal adrenal steroid blockade in children with congenital adrenal hyperplasia$0
ZIA · FY2025 · CL · contact PI
Modified-release Hydrocortisone Therapy as a Treatment for Adrenal Insufficiency$0
ZIA · FY2025 · CL · contact PI
Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2$0
ZIA · FY2025 · CL · contact PI
Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia$0
ZIA · FY2025 · CL · contact PI
Natural History Study of Patients with Excess Androgen$0
ZIA · FY2025 · CL · contact PI
Novel treatment approaches: sex steroid blockade in children$0
ZIA · FY2024 · CL · contact PI
Natural History Study of Patients with Excess Androgen$0
ZIA · FY2024 · CL · contact PI
Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia$0
ZIA · FY2024 · CL · contact PI
Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2$0
ZIA · FY2024 · CL · contact PI
Modified-release Hydrocortisone Therapy as a Treatment for CAH$0
ZIA · FY2024 · CL · contact PI
Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia$0
ZIA · FY2023 · CL · contact PI
Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2$0
ZIA · FY2023 · CL · contact PI
Modified-release Hydrocortisone Therapy as a Treatment for CAH$0
ZIA · FY2023 · CL · contact PI
Novel treatment approaches: sex steroid blockade in children$0
ZIA · FY2023 · CL · contact PI
Natural History Study of Patients with Excess Androgen$0
ZIA · FY2023 · CL · contact PI
Study of a corticotropin releasing factor-1 receptor antagonist for the treatment of congenital adrenal hyperplasia$0
ZIA · FY2022 · CL · contact PI
Novel treatment approaches: sex steroid blockade in children$0
ZIA · FY2022 · CL · contact PI
Natural History Study of Patients with Excess Androgen$0
ZIA · FY2022 · CL · contact PI
Modified-release Hydrocortisone Therapy as a Treatment for CAH$0
ZIA · FY2022 · CL · contact PI
Gene Therapy for Congenital Adrenal Hyperplasia through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2$0
ZIA · FY2022 · CL · contact PI
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia$0
ZIA · FY2020 · CL · contact PI
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia$0
ZIA · FY2019 · CL · contact PI
Phase 2 Multi-center Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia$0
ZIA · FY2018 · CL · contact PI